Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.49 |
| ▸ | PTAFR | P25105 | 4/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958679 | 0.95 | TDP1 (0.56) | TDP1L3MBTL1HRH1CYP2A6PTAFR | |
| SCHEMBL7760926 | 0.82 | TDP1 (0.64) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL4958248 | 0.81 | TDP1 (0.62) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL5879435 | 0.81 | TDP1 (0.57) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL1741942 | 0.79 | TDP1 (0.60) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485675 | 0.79 | TDP1 (0.80) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL724788 | 0.79 | TDP1 (0.80) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL12606607 | 0.78 | TAAR1 (0.60) | TBXAS1CHRNB2CHRNA4 | |
| SCHEMBL12197971 | 0.78 | TDP1 (0.62) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| Hydrochloric Acid SCHEMBL1740801 | 0.78 | TDP1 (0.58) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | claimed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | claimed |
| EP-1997806-A1 | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders | Targacept, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-6603011-B1 | Representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine; the prevention and treatment of CNS disorders which have been attributed to neurotransmitter system dysfunction | TARGACEPT, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6555684-B2 | A pyridine or pyrimidine derivatives containing primary, secondary or tertiary amine group | TARGACEPT, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | disclosed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | PMP22, AANAT, CHAT | TDP1 1227/4885L3MBTL1 4001/4885HRH1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.